New Two-Drug combo aims to beat back returning myeloma
NCT ID NCT07463807
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study compares a new combination of teclistamab and pomalidomide against the standard treatment (carfilzomib, pomalidomide, and dexamethasone) for multiple myeloma that has come back after improvement. About 162 adults with relapsed or refractory myeloma will take part. The goal is to see if the new combo is safe and can lower cancer cells to undetectable levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
teclistamab and pomalidomide
What this could lead to
If successful, this could offer a more effective, fixed-duration treatment option for people with multiple myeloma that has come back after initial therapy.
What could go wrong
This is an early-phase (Ib/II) trial with a small number of participants, so results may not apply broadly. The new combination may cause side effects or not work better than the standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.